Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?
作者信息
Solomon Daniel H, Bitton Asaf, Katz Jeffrey N, Radner Helga, Brown Erika M, Fraenkel Liana
机构信息
Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
Arthritis Rheumatol. 2014 Apr;66(4):775-82. doi: 10.1002/art.38323.
Abstract
摘要
相似文献
1
Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?综述：类风湿关节炎的达标治疗：事实、虚构还是假设？
Arthritis Rheumatol. 2014 Apr;66(4):775-82. doi: 10.1002/art.38323.
2
Rethinking the discordance between guidelines and practice in rheumatoid arthritis treatment.重新审视类风湿关节炎治疗指南与实践之间的不一致性。
Med J Aust. 2011 Oct 17;195(8):446-7. doi: 10.5694/mja11.10068.
3
Management of rheumatoid arthritis: what happens and what does not happen in real life.类风湿关节炎的管理：现实生活中发生了什么以及未发生什么。
Rheumatol Int. 2016 Feb;36(2):167-8. doi: 10.1007/s00296-015-3402-2. Epub 2015 Dec 19.
4
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.我们如何在有恶性肿瘤病史的类风湿性关节炎患者中使用生物制剂？使用斯堪的纳维亚登记册对治疗模式进行评估。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001363.
5
Roundtable I: Practice patterns for treating rheumatoid arthritis.圆桌会议一：类风湿关节炎的治疗实践模式
Am J Manag Care. 1999 Sep;5(14 Suppl):S870-9.
6
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.在NEO-RACo试验中，医生坚持治疗达标策略对早期类风湿关节炎治疗结果的影响。
Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.
7
Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. A survey of Alabama rheumatologists.改善病情抗风湿药物联合治疗类风湿关节炎。阿拉巴马州风湿病学家调查。
Arthritis Care Res. 1991 Mar;4(1):48-51. doi: 10.1002/art.1790040109.
8
Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.日本临床实践中类风湿关节炎达标治疗策略实施的障碍
Mod Rheumatol. 2015 Jan;25(1):43-9. doi: 10.3109/14397595.2014.926607. Epub 2014 Jun 20.
9
Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.澳大利亚药品福利计划对生物性抗风湿药物限制的变更，已对来氟米特的使用产生了影响。
Int J Rheum Dis. 2017 Nov;20(11):1795-1797. doi: 10.1111/1756-185X.12717. Epub 2015 Jul 14.
10
Rheumatoid arthritis in elderly and young patients.老年和年轻患者的类风湿性关节炎。
Rev Bras Reumatol Engl Ed. 2017 Sep-Oct;57(5):491-494. doi: 10.1016/j.rbre.2015.06.002. Epub 2015 Oct 27.
引用本文的文献
1
The Feasibility and Impact of Implementing Interventions to Reduce Short-Acting β-Agonist Over-Reliance in Asthma: An Expert Opinion.实施干预措施以减少哮喘患者对短效β受体激动剂过度依赖的可行性及影响：专家意见
Adv Ther. 2025 Aug 6. doi: 10.1007/s12325-025-03293-6.
2
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.倍利珠单抗推进重度哮喘缓解：最新发现、当前观点及未来方向
Clin Exp Allergy. 2025 Jul;55(7):521-531. doi: 10.1111/cea.70083. Epub 2025 May 30.
3
Clinicians' perspectives concerning treatment initiation and escalation strategies for digital ulcers in patients with systemic sclerosis.临床医生对系统性硬化症患者指端溃疡治疗起始及强化策略的看法。
J Scleroderma Relat Disord. 2025 Apr 30:23971983251336616. doi: 10.1177/23971983251336616.
4
Remote-Customized Telecontrol for Patients with Rheumatoid Arthritis: The iARPlus (Innovative Approach in Rheumatology) Initiative.类风湿性关节炎患者的远程定制遥控：iARPlus（风湿病学创新方法）倡议。
J Pers Med. 2025 Jan 16;15(1):30. doi: 10.3390/jpm15010030.
5
Rituximab use in Rheumatoid Arthritis: A Seven-Year Retrospective Study of 52 Patients at a Saudi Arabian Hospital.利妥昔单抗在类风湿关节炎中的应用：沙特阿拉伯一家医院的 52 例患者的 7 年回顾性研究。
Med Sci Monit. 2024 Dec 1;30:e946178. doi: 10.12659/MSM.946178.
6
Immunomodulatory effect of sp. in mononuclear cells extracted from the blood of rheumatoid arthritis patients.[某种物种]对类风湿关节炎患者血液中提取的单核细胞的免疫调节作用
J Venom Anim Toxins Incl Trop Dis. 2024 Sep 16;30:e20230064. doi: 10.1590/1678-9199-JVATITD-2023-0064. eCollection 2024.
7
Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis.基线中性粒细胞与淋巴细胞比值高的患者对非戈替尼治疗类风湿关节炎的反应更好。
Rheumatol Ther. 2024 Oct;11(5):1383-1392. doi: 10.1007/s40744-024-00695-w. Epub 2024 Jul 10.
8
Distinct oral DNA viral signatures in rheumatoid arthritis: a Pilot study.类风湿关节炎中独特的口腔DNA病毒特征：一项初步研究。
J Oral Microbiol. 2024 May 1;16(1):2348260. doi: 10.1080/20002297.2024.2348260. eCollection 2024.
9
Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments.白细胞介素（IL-1）介导的自身炎症性疾病的优化治疗：基于疾病活动度调整治疗的影响
J Clin Med. 2024 Apr 17;13(8):2319. doi: 10.3390/jcm13082319.
10
"How are you?" Perspectives From Patients and Health Care Providers of Text Messaging to Support Rheumatoid Arthritis Care: A Thematic Analysis.“你好吗？”类风湿关节炎护理支持短信的患者及医疗服务提供者视角：一项主题分析
ACR Open Rheumatol. 2024 May;6(5):276-286. doi: 10.1002/acr2.11652. Epub 2024 Feb 20.
本文引用的文献
1
High disease activity may not be sufficient to escalate care.高疾病活动度可能不足以升级治疗。
Arthritis Care Res (Hoboken). 2014 Feb;66(2):197-203. doi: 10.1002/acr.22098.
2
Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes.患者对实现达标治疗目标的看法：对患者报告结局的批判性审视。
Arthritis Care Res (Hoboken). 2013 Oct;65(10):1707-12. doi: 10.1002/acr.22048.
3
Treat-to-target trials: uses, interpretation and review of concepts.达标治疗试验：概念的应用、解读与综述
Diabetes Obes Metab. 2014 Mar;16(3):193-205. doi: 10.1111/dom.12129. Epub 2013 Jun 14.
4
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.2008年美国风湿病学会关于使用改善病情抗风湿药和生物制剂治疗类风湿关节炎的建议的2012年更新版。
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
5
Treating rheumatoid arthritis to target: the patient version of the international recommendations.达标治疗类风湿关节炎：国际建议的患者版。
Ann Rheum Dis. 2011 Jun;70(6):891-5. doi: 10.1136/ard.2010.146662. Epub 2011 Apr 7.
6
Long-term effects of intensive glucose lowering on cardiovascular outcomes.强化血糖控制对心血管结局的长期影响。
N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.
7
Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.医疗保险管理式医疗计划中类风湿关节炎患者接受疾病修正抗风湿药物治疗的情况。
JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.
8
Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective.老年人新诊断类风湿关节炎的优质护理：加拿大视角。
Arthritis Care Res (Hoboken). 2011 Jan;63(1):53-7. doi: 10.1002/acr.20304.
9
Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis.患者与医生对类风湿关节炎整体疾病严重程度评估的不一致性。
Arthritis Care Res (Hoboken). 2010 Jun;62(6):857-64. doi: 10.1002/acr.20132.
10
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.类风湿关节炎治疗方案的经济学方面：系统文献复习为 EULAR 类风湿关节炎管理建议提供信息。
Ann Rheum Dis. 2010 Jun;69(6):995-1003. doi: 10.1136/ard.2009.126714. Epub 2010 May 6.
Zotero 插件